Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative ColitisWilliam J. Sandborn, Paul Rutgeerts, Cynthia Guzzo et al.|Gastroenterology|2013Cited by 938
Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative ColitisWilliam J. Sandborn, Paul Rutgeerts, Brian G. Feagan et al.|Gastroenterology|2013Cited by 725
Clinical Response Is a Meaningful Endpoint in Ulcerative Colitis Clinical StudiesWilliam J. Sandborn, Paul Rutgeerts, Brian Feagan et al.|Inflammatory Bowel Diseases|2012Cited by 3
P142 Subcutaneously administered golimumab induction therapy improves health states measured by EQ-5D in patients with moderately to severely active ulcerative colitis: results from PURSUIT-SCPeter G. Gibson, W. Sandborn, B. Feagan et al.|Journal of Crohn s and Colitis|2013Cited by 2
Impact of Golimumab SC on Disease Specific and Generic HRQoL in Patients With Moderately to Severely Active UC: PURSUIT-SC InductionBrian G. Feagan, William J. Sandborn, Peter G. Gibson et al.|Inflammatory Bowel Diseases|2012Cited by 2